HLA-C and lung cancer: As demonstrated in preclinical and translational model of non‐small cell lung cancer (NSCLC), the addition of avelumab to cetuximab could enhance the activation of natural killer (NK) cells, thus increasing antibody‐dependent cell‐mediated cytotoxicity (ADCC), activating the interaction of NK with dendritic cells, and enhancing major histocompatibility complex (MHC) class II molecule expression, which could result in more effective cetuximab‐induced cancer cell death.18